LINC01605 and triple-negative breast carcinoma: LINC01605 has been demonstrated in triple negative breast cancer, nasopharyngeal carcinoma, colorectal cancer, and other cancers to promote tumor proliferation and invasion through multiple pathways (Hu et al., 2021b; Wang et al., 2022a; Zhao et al., 2022).